Geode Capital Management LLC Purchases 56,936 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA)

Geode Capital Management LLC raised its position in Ikena Oncology, Inc. (NASDAQ:IKNA) by 21.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 327,962 shares of the company’s stock after buying an additional 56,936 shares during the quarter. Geode Capital Management LLC owned about 0.68% of Ikena Oncology worth $538,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in IKNA. JPMorgan Chase & Co. boosted its holdings in shares of Ikena Oncology by 18,244.1% in the 4th quarter. JPMorgan Chase & Co. now owns 155,741 shares of the company’s stock valued at $255,000 after purchasing an additional 154,892 shares in the last quarter. Peapod Lane Capital LLC acquired a new position in shares of Ikena Oncology during the 4th quarter worth $833,000. Finally, BML Capital Management LLC lifted its position in shares of Ikena Oncology by 395.8% during the 4th quarter. BML Capital Management LLC now owns 3,585,866 shares of the company’s stock worth $5,881,000 after buying an additional 2,862,578 shares during the last quarter. 75.00% of the stock is currently owned by institutional investors and hedge funds.

Ikena Oncology Stock Up 2.5 %

Ikena Oncology stock opened at $1.25 on Friday. The stock has a market cap of $60.32 million, a PE ratio of -1.02 and a beta of 0.48. Ikena Oncology, Inc. has a 12-month low of $0.97 and a 12-month high of $1.94. The business’s 50-day moving average price is $1.25 and its two-hundred day moving average price is $1.48.

Ikena Oncology (NASDAQ:IKNA) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. As a group, analysts expect that Ikena Oncology, Inc. will post -0.91 earnings per share for the current year.

Ikena Oncology Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.